What is Merck & Co.'s alliance revenue - lenvima — intangible assets?

Merck & Co. (MRK) reported alliance revenue - lenvima — intangible assets of $188.00M in Q1 2026.

How has Merck & Co.'s alliance revenue - lenvima — intangible assets changed year-over-year?

Merck & Co.'s alliance revenue - lenvima — intangible assets decreased by 50.8% year-over-year, from $382.00M to $188.00M.

What is the long-term trend for Merck & Co.'s alliance revenue - lenvima — intangible assets?

Over 2 years (2023 to 2025), Merck & Co.'s alliance revenue - lenvima — intangible assets has grown at a -37.6% compound annual growth rate (CAGR), from $2.99B to $1.17B.

What does alliance revenue - lenvima — intangible assets mean?

The book value of non-physical assets like patents or licenses related to a specific product.

Discontinued — last reported Q1 '26

Products & Services · Intangible assets

Alliance revenue - Lenvima — Intangible assets

Merck & Co. Alliance revenue - Lenvima — Intangible assets decreased by 6.5% to $188.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.8%, from $382.00M to $188.00M. Over 2 years (FY 2023 to FY 2025), Alliance revenue - Lenvima — Intangible assets shows a downward trend with a -37.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryCapital Allocation

SignalHigher is better

VolatilityStable

First reportedQ3 2018

Last reportedQ1 2026

Rolls up toIntangible assets — net

How to read this metric

A stable or increasing value suggests continued investment in the product's long-term commercial potential.

Detailed definition

The carrying value of non-physical assets, such as acquired intellectual property, patents, or marketing rights, associa...

Peer comparison

Standard asset reporting for companies holding significant intellectual property portfolios.

Metric ID: mrk_segment_alliance_revenue_lenvima_intangible_assets

Historical Data

18 periods

	Q2 '21	Q3 '21	Q1 '22	Q2 '22	Q3 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$1.00B	$1.00B	$973.00M	$920.00M	$867.00M	$812.00M	$756.00M	$743.00M	$683.00M	$623.00M	$563.00M	$502.00M	$442.00M	$382.00M	$321.00M	$261.00M	$201.00M	$188.00M
QoQ Change	—	+0.0%	-2.7%	-5.4%	-5.8%	-6.3%	-6.9%	-1.7%	-8.1%	-8.8%	-9.6%	-10.8%	-12.0%	-13.6%	-16.0%	-18.7%	-23.0%	-6.5%
YoY Change	—	—	—	-8.0%	-13.3%	-16.5%	-17.8%	-14.3%	—	-23.3%	-25.5%	-32.4%	-35.3%	-38.7%	-43.0%	-48.0%	-54.5%	-50.8%

Range$188.00M – $1.00B

CAGR-32.5%

Avg YoY Growth-30.1%

Median YoY Growth-29.0%

Current Streak16 quarters decline

Similar Metrics at Other Companies

AmgenAMGN View metric

AbbVieABBV View metric

AmgenAMGN View metric

AbbVieABBV View metric

Altria GroupMO View metric

Frequently Asked Questions

What is Merck & Co.'s alliance revenue - lenvima — intangible assets?: Merck & Co. (MRK) reported alliance revenue - lenvima — intangible assets of $188.00M in Q1 2026.
How has Merck & Co.'s alliance revenue - lenvima — intangible assets changed year-over-year?: Merck & Co.'s alliance revenue - lenvima — intangible assets decreased by 50.8% year-over-year, from $382.00M to $188.00M.
What is the long-term trend for Merck & Co.'s alliance revenue - lenvima — intangible assets?: Over 2 years (2023 to 2025), Merck & Co.'s alliance revenue - lenvima — intangible assets has grown at a -37.6% compound annual growth rate (CAGR), from $2.99B to $1.17B.
What does alliance revenue - lenvima — intangible assets mean?: The book value of non-physical assets like patents or licenses related to a specific product.